Identification of 1‐phenoxy‐3‐(piperazin‐1‐yl)propan‐2‐ol derivatives as novel triple reuptake inhibitors

Author:

Ashrafuzzaman Md.12,Ji Su Hyun13,Ahn Hyomin14,Chung Hwan Won5,Choi Daeun1,Park Ju Jin1,Go Minji1,Pyo Jung In1,Shafioul Azam Sharif Mohammed1,Lee Duck‐Hyung3ORCID,Chi Sung‐Gil4,Song Chiman1,Cheong Chan Seong1,Han Seo‐Jung12ORCID

Affiliation:

1. Chemical & Biological integrative Research Center Korea Institute of Science and Technology Seoul South Korea

2. Division of Bio‐Medical Science & Technology, KIST School University of Science and Technology Seoul South Korea

3. Department of Chemistry Sogang University Seoul South Korea

4. Department of Life Sciences Korea University Seoul South Korea

5. Computational Science Research Center Korea Institute of Science and Technology Seoul South Korea

Abstract

AbstractNovel 1‐phenoxy‐3‐(piperazin‐1‐yl)propan‐2‐ol derivatives were designed and synthesized as potential triple reuptake inhibitors, which simultaneously inhibit serotonin, norepinephrine, and dopamine transporters (SERT, NET, and DAT, respectively). Through neurotransmitter transporter uptake assays, inhibitory activities of 1‐phenoxy‐3‐(piperazin‐1‐yl)propan‐2‐ol derivatives were evaluated. We discovered compound 19 exhibited the most potent inhibitory activities against all three monoamine neurotransmitter transporters and the IC50 values of 19 against SERT, NET, and DAT were determined. In addition, binding modes of 19 with SERT, NET, and DAT were predicted by docking studies.

Funder

Korea Institute of Science and Technology

National Research Council of Science and Technology

Korea Drug Development Fund

National Research Foundation

Publisher

Wiley

Subject

General Chemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3